Form 4: Vivo Opportunity, LLC Sells Shares of Soleno Therapeutics Inc (SLNO)

Vivo Opportunity, LLC, a 10% owner of Soleno Therapeutics Inc, reports selling shares of common stock over three days in March 2025.

Summary

• Vivo Opportunity, LLC, along with Vivo Opportunity Fund Holdings, L.P., filed a Form 4 detailing changes in beneficial ownership of Soleno Therapeutics Inc (SLNO).
• The transactions involved the sale of common stock on March 26, 27, and 28, 2025.
• On March 26, 2025, 400,000 shares were sold at a weighted average price of $65.8, reducing holdings to 5,891,851 shares held indirectly by Vivo Opportunity Fund Holdings, L.P.
• On March 27, 2025, 1,100,000 shares were sold at a weighted average price of $67.8, further reducing holdings to 4,791,851 shares.
• On March 28, 2025, an additional 333,557 shares were sold at a weighted average price of $70.6, resulting in a final holding of 4,458,294 shares.
• The sales were executed on the open market in multiple transactions at varying prices within specified ranges.
• Vivo Opportunity, LLC disclaims beneficial ownership except to the extent of its pecuniary interest.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the large sale of shares by a significant shareholder, which could indicate a lack of confidence or a strategic shift away from the company.

Negatives

• The sale of a significant number of shares by a major shareholder could be interpreted negatively by the market.

Risks

• Continued selling pressure from Vivo Opportunity, LLC could further depress the stock price.
• The market may react negatively to the reduced stake of a major shareholder, potentially impacting investor confidence.

Industry Context

Sales by significant shareholders are common and are closely monitored by investors for insights into the company's prospects and the shareholder's confidence.

Comparison to Industry Standards

• Comparing these transactions to similar sales by major shareholders in comparable biotech companies would provide context on whether this is a typical portfolio adjustment or a signal of concern.
• For example, if other major shareholders in peer companies like Aclaris Therapeutics or AnaptysBio have been reducing their stakes, it might indicate a broader trend in the sector.

Stakeholder Impact

• Shareholders may experience a decrease in stock value due to the selling pressure.
• Employee morale could be affected by the perceived lack of confidence from a major shareholder.

Key Dates

Keywords

Soleno Therapeutics, SLNO, Vivo Opportunity, Share Sale, Beneficial Ownership, Form 4